NDC product
Talzenna
NDC 63539-295 · U.S. Pharmaceuticals
Key facts
| Product NDC | 63539-295 |
|---|---|
| Proprietary name | Talzenna |
| Nonproprietary name | talazoparib |
| Substances | TALAZOPARIB TOSYLATE |
| Dosage form | CAPSULE |
| Route | ORAL |
| Labeler | U.S. Pharmaceuticals |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Application number | NDA211651 |
| Pharmacologic classes | Poly(ADP-Ribose) Polymerase Inhibitor [EPC], Poly(ADP-Ribose) Polymerase Inhibitors [MoA] |
| Marketing start | Dec 10, 2018 |
| Marketing end | Jan 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory